ClinicalTrials.gg
WithdrawnNCT02090348TECNERGYUpdated Sep 7, 2015

Study to Evaluate Fatigue in Participants With Relapsing Remitting Multiple Sclerosis When Treated With Dimethyl Fumarate

A Phase 4 interventional study of dimethyl fumarate in Relapsing-Remitting Multiple Sclerosis and Multiple Sclerosis, sponsored by Biogen. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-09-07.

Sponsored by Biogen · Phase 4, Interventional, and Treatment

Why this study was withdrawn
The study was withdrawn for business reasons. The decision to stop the TECNERGY study was not a result of any safety or efficacy concerns.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, Relapsing-Remitting — none open to participants now, none under way, none of them phase 3. Dimethyl Fumarate · Multiple Sclerosis, Relapsing-Remitting.

Enrollment
19th of 22
0 · median 61
Started
2015
with 5 others
Phase 4
9 of 22
none open now
Registered
8th of 22
by date
Lead sponsor
18 of 22
Biogen

Among the 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, Relapsing-Remitting, this one is the 19th largest by enrollment, is one of 6 that started in 2015, is one of 9 in phase 4, and was the 8th registered.

Multiple Sclerosis, Relapsing-Remitting

618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.

Browse Multiple Sclerosis, Relapsing-Remitting studies →

Open to participants now

None of the 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, Relapsing-Remitting is open now. The open studies under Multiple Sclerosis, Relapsing-Remitting, anywhere →

About Dimethyl Fumarate

Dimethyl Fumarate: first FDA approval 2013 (TECFIDERA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 61 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 44 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, Relapsing-Remitting as a file.
02

Study summary

The primary objective of this study is to determine whether dimethyl fumarate (DMF) taken over 12 months is effective in reducing Multiple Sclerosis (MS)-related fatigue, as measured by mean changes in the Fatigue Scale for Motor and Cognitive Functions (FSMC), in participants with relapsing-remitting multiple sclerosis (RRMS). The secondary objectives of this study are: To investigate changes from Baseline in FSMC and fatigue severity (Fatigue Severity Scale [FSS]) at 1, 3, 6, 9, and 12 months in participants receiving DMF; To assess the impact of DMF on patient-reported outcomes (PROs), including work productivity (Work Productivity and Activity Impairment-Multiple Sclerosis questionnaire [WPAI-MS]), health-related quality of life (Short Form Health Survey [SF-12]), depression (Beck Depression Inventory-Fast Screen [BDI-FS]), and sleepiness (Epworth Sleepiness Scale [ESS]) at 6 and 12 months in participants receiving DMF; To examine whether an association exists between fatigue and baseline demographics (e.g., age and sex) and disease characteristics (e.g., disease duration, baseline disease activity, treatment history, expanded disability status scale [EDSS] score, and PROs); To assess any changes in fatigue-related medication use.

03

Conditions studied

  • Relapsing-Remitting Multiple Sclerosis
  • Multiple Sclerosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Have a confirmed diagnosis of RRMS and satisfies the therapeutic indication as described in the local label.
  • Have a stable EDSS (as assessed by the Investigator) and been on the same (type and dosage) standard of care (SOC) treatment for at least 6 months.
  • If taking antidepressants, amphetamine, modafinil, or fampridine (Fampyra), subject must be assessed as having been clinically stable for at least 3 months prior to the Baseline Visit.
  • FSMC total score ≥43 (mild fatigue) at Baseline.
  • As perceived by the Investigator, have the ability to comply with all requirements of the study protocol.

Key Exclusion Criteria:

  • Diagnosis of major depression, as identified by the Investigator.
  • Diagnosis of primary progressive, secondary progressive, or progressive relapsing multiple sclerosis.
  • History of (except for basal cell carcinoma that had been completely excised prior to study entry), severe allergic or anaphylactic reactions or known drug , abnormal laboratory results indicative of any significant disease, and/or a major disease that would preclude participation in a clinical trial.
  • Treatment of MS relapse within 90 days prior to study enrollment.
  • History of a positive test result for , virus antibody, or virus (defined as positive for hepatitis B surface antigen or hepatitis B core antibody.
  • Impaired hepatic or renal function, as perceived by the Investigator.
  • Any prior treatment with DMF (or other fumarate derivative), total lymphoid irradiation, cladribine, fingolimod, T cell or T-cell receptor vaccination, or any therapeutic monoclonal antibody.
  • Current enrollment in any other clinical studies.
  • Known to suffer from narcolepsy or another significant sleep disorder.
  • Comorbidity that may have an impact on fatigue.
  • Other unspecified reasons that, in the opinion of the Investigator or Biogen Idec, make the subject unsuitable for enrollment.

NOTE: Other protocol-defined Inclusion/Exclusion Criteria May Apply

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    dimethyl fumarate

    DMF at a dose of 120 mg twice a day (BID) for the first 7 days and 240 mg BID for the remainder of study period (up to 12 months)

    Drug: dimethyl fumarate

Interventions

  • Administered as specified in the treatment arm

    Also known as: DMF, BG00012, Tecfidera

06

What researchers measure

Primary outcomes

  1. Mean change from baseline in MS-related fatigue as assessed by FSMC at 12 months in participants receiving DMF

    FSMC is a 20-item questionnaire and produces a score between 1 and 5 for each scored question (ranging from "does not apply at all" to "applies completely"). Items are summed to generate a total score and transformed to a scale with a range of 20 to 100, where higher scores indicate higher levels of fatigue

    Time frame: 12 months

Secondary outcomes

  1. Mean change from baseline in fatigue as assessed by FSMC in participants receiving DMF

    Time frame: Baseline and 1, 3, 6, 9 and 12 months

  2. Mean change from baseline in fatigue as assessed by FSS in participants receiving DMF

    The Fatigue Severity Scale (FSS) is designed to differentiate fatigue from clinical depression, since both share some of the same symptoms. FSS consists of answering a 9-item questionnaire that requires the participant to rate his or her own level of fatigue. Each question produces a score between 1 to 7. The scoring is done by calculating the average response to the questions. Participants with depression alone score about 4.5. But people with fatigue related to MS average about 6.5

    Time frame: Baseline and 1, 3, 6, 9 and 12 months

  3. Mean change from baseline in work productivity as assessed by WPAI-MS, in participants receiving DMF

    The Work Productivity and Activity Impairment (WPAI) questionnaire is a validated instrument to measure impairments in work and activities. The WPAI yields four types of scores: 1. Absenteeism (work time missed) 2. Presenteesism (impairment at work / reduced on-the-job effectiveness) 3. Work productivity loss (overall work impairment / absenteeism plus presenteeism) 4. Activity Impairment. WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity

    Time frame: Baseline and 6, 12 months

  4. Mean change from baseline in quality of life as assessed by SF-12 in participants receiving DMF

    The SF-12 is a multipurpose short form survey with 12 questions, all selected from the SF-36 Health Survey. The questions were combined, scored, and weighted to create two scales that provide glimpses into mental and physical functioning and overall health-related-quality of life. Physical and Mental Health Composite Scores (PCS \& MCS) are computed using the scores of twelve questions and range from 0 to 100, where a zero score indicates the lowest level of health and 100 indicates the highest level of health

    Time frame: Baseline and 6, 12 months

  5. Mean change from baseline in depression as assessed by BDI-FS in participants receiving DMF

    BDI-FS is a self-report inventory for measuring the severity of depression on a 7-item questionnaire. Each question is rated on a 4-point scale (0 - 3) to assess frequency, over the past two weeks, of feelings of sadness, pessimism (hopelessness), sense of failure, loss of a sense of pleasure, loss of self-confidence, self-blame, and suicidal ideation. The total ESS score is the sum of 8 item-scores and can range between 0 and 21, where higher scores indicate higher levels of depression

    Time frame: Baseline and 6, 12 months

  6. Mean change from baseline in sleepiness assessed by ESS in participants receiving DMF

    The ESS is a self-administered 8-item questionnaire with that provides a measure of a person's general level of daytime sleepiness, or their average sleep propensity in daily life. Each question is rated on a 4-point scale (0 - 3), their usual chances of dozing off or falling asleep in 8 different situations or activities that most people engage in as part of their daily lives, although not necessarily every day. The total ESS score is the sum of 8 item-scores and can range between 0 and 24, where higher scores indicate higher levels of a person's level of daytime sleepiness

    Time frame: Baseline and 6, 12 months

  7. Change in MS-related fatigue (FSMC) status

    Improved (\> 4.5 increase), Stable (within ±4.5), and Worsened (\> 4.5 decrease)

    Time frame: Baseline and up to 12 months

  8. Correlation of fatigue with baseline demographics and disease characteristics

    Time frame: Baseline and up to 12 months

  9. Proportion of participants with reduced dose or discontinuation of fatigue-related medications

    Time frame: 6 and 12 months

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2015, a primary completion of Oct 2017 and a completion of Oct 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2014
First posted
Mar 18, 2014
Start
Jun 2015
Primary completionEst.
Oct 2017
CompletionEst.
Oct 2017
Last update
Sep 7, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 7, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02090348
Lead sponsor
Biogen
Responsible party
Sponsor
First posted
Mar 18, 2014
Start date
Jun 2015
Primary completion
Oct 2017 (estimated)
Completion
Oct 2017 (estimated)
Last update
Sep 7, 2015

Study contacts

Medical Director
study director · Biogen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dimethyl Fumarate

Start the discussion